Introduction {#sec1-1}
============

Tuberculosis is one of the most prevalent infections of human beings and a formidable public health challenge that shows little sign of abating \[[@ref1]\]. Primary infection with *M. tuberculosis* leads to clinical disease in only \~ 10% of individuals. In the remaining cases, the ensuing immune response arrests the further growth of *M. tuberculosis*. However, the pathogen is completely eradicated in only \~ 10% people, while the immune response in the remaining \~ 90% individuals only succeeds in the containment of infection as some bacilli escape killing by blunting the microbicide mechanisms of immune cells and remain in no replicating (dormant or latent) state in old lesions. The process is termed as latent tuberculosis infection (LTBI) and is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB \[[@ref2]\].

Persons with LTBI do not have active tuberculosis and do not feel sick but may develop it in the near or remote future, a process called TB reactivation \[[@ref3]\]. The lifetime risk of reactivation TB for a person with documented LTBI is estimated to be 5 -10%, with the majority developing TB disease within the first five years after initial infection and lifetime risk, is \~ 50% in HIV coinfected individuals \[[@ref4]\]\[[@ref5]\]. However, the risk of developing TB disease following infection depends on several factors, the most important one being the immunological status of the host. Finding LTBI provides an opportunity to treat and prevent reactivation of the latent infection that leads to active disease, especially in people with compromised immune systems.

Systematic diagnosis and treatment of LTBI is part of the new End TB strategy by World Health Organization (WHO) and achieving ≥ 90% LTBI treatment coverage among people living with HIV (PLHIV), and child contacts of TB cases are one of the global priority targets \[[@ref6]\].

Available tests to demonstrate prior tuberculosis infection include the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) \[[@ref7]\].

In the Republic of Macedonia, the systematic screening for LTBI and treating people who have risk factors for developing active TB is part of the National tuberculosis program (NTP). The Macedonian national guideline for LTBI updated in 2016, recommends three main groups with risk factors for management of LTBI: children as household contacts of pulmonary TB cases, PLHIV and patients initiating anti-TNF treatment or receiving immunosuppressive therapy.

The study aims to present our first results with IGRA test compared with TST in the screening of LTBI and the treatment results in the cases with LTBI.

Material and Methods {#sec1-2}
====================

A retrospective cohort study was undertaken, based on data systematically collected on all persons undergoing the TST-based and the IGRA-based LTBI screening programme and treatment programme during 2016. All data were obtained from the Central unit for registration of TB and LTBI in the Republic of Macedonia, at the Institute for Lung Diseases and TB. In this study 73 cases diagnosed and treated with LTBI were included. For diagnosis of LTBI, we used TST RT-23 5T.U. and induration ≥ 5 mm was considered as positive results. The other test was commercial IGRA such as QuantiFERON-TB Gold In-Tube (QFT-IT), and it was performed by measuring interferon-ɣ (IFN-ɣ) with Enzyme-Linked Immunosorbent Assay (ELISA). In the most cases, diagnosis of LTBI was obtained with both tests: with the exception that TST and IGRA test was not performed in 11 (15.07%) and 36 (49.1%) cases respectively. According to our national guidelines for treatment of LTBI, there are two used therapeutic regimes: the daily regime of Isoniazid (H) for 6 months or daily regime of Isoniazid and Rifampicin (R) for 3 months. All cases with LTBI were followed during the treatment period, and the treatment outcomes were presented.

The differences of category variables were present with the distribution of the frequencies. For comparison of the differences of the data Fischer-exact test was used. A statistical difference was considered to be significant when the p-value was \< 0.05.

Results {#sec1-3}
=======

Of 73 cases with LTBI, 61.64% were men, and 38.36% were women. According to the age, 61 (83.56%) were children, and 12 (16.43) were adults. Among all age groups, the most frequent were cases between 5and 14 years old (54.79%), [Table 1](#T1){ref-type="table"}.

###### 

Distribution of cases with LTBI according to the gender and age groups

  Gender               n (%)
  -------------------- ------------------
   Men                 45 (61.64)
   Women               28 (38.36)
   Total               73 (100.00)
  Age groups           n (%)
    0 -- 4             21 (28.77)
    5 -- 14            40 (54.79)
   15 -- 24            2 (2.74)
   25 -- 34            4 (5.48)
   35 -- 44 45 -- 54   0 (0,%) 5 (6.85)
   55 -- 64            1 (1.37)
   Total               73 (100.00)

In this study three groups of cases with risk factors were screened for LTBI and the most frequent were children household contacts with pulmonary TB cases (61-83.65%), followed by PLHIV (9-12.33%) and only 3 cases with other medical reasons: 1 case that initiated anti TNF therapy and 2 that received immunosuppressive therapy, named as others ([Table 2](#T2){ref-type="table"}). According to the data from our NTP, in 2016 among 360 TB contacts examined, 15 were TB cases (4.16%), and 61 were with LTBI (16.9%).

###### 

Different groups with risk factors for the screening of LTBI

  Risk groups             n (%)
  ----------------------- -------------
  Contact with TB cases   61 (83.56)
  PLHIV                   9 (12.33)
  Others                  3 (4.11)
  Total                   73 (100.00)

In [Table 3](#T3){ref-type="table"} and [Table 4](#T4){ref-type="table"} the results obtain with TST, and IGRA test was separately presented. In [Table 5](#T5){ref-type="table"} the combination of both tests was presented, and it is obvious that in all cases included in the study one or both tests were performed.

###### 

Results of TST at the time of screening for LTBI

  TST test                n (%)
  ----------------------- -------------
  Negative                28 (38.36)
  Positive :5 -- 14mm     11 (15.07)
  Positive :15 -- 20mm    18 (24.66)
  Positive : 20 -- 34mm   5 (6.85)
  Not done                11 (15.07)
  Total                   73 (100.00)

###### 

Results of IGRA test at the time of screening of LTBI

  IGRA test   n (%)
  ----------- -------------
  Negative    12 (16.44)
  Positive    25 (34.25)
  Not done    36 (49.31)
  Total       73 (100.00)

###### 

Combination of TST and IGRA

  Test           IGRA pos   IGRA neg   IGRA not done   Total
  -------------- ---------- ---------- --------------- -------
  TST pos        10         5          19              34
  TST neg        5          6          17              28
  TST not done   10         1          /               11
  Total          25         12         36              73

Even we used to perform both tests in each case; there were 11 cases without TST and 36 without IGRA test. TST confirmed 34 positive cases (46.57%), IGRA test 25 positive cases (34.25%) and both tests were positive in 11 cases (15.06%) and both negative in 6 cases (8.21%).

There were 17 cases in which only TST was performed and 1case in which only IGRA was performed, and the results were negative. Those 18 and those 6 cases were both tests confirmed to be negative, were without laboratory confirmation for LTBI (Total 24).

In Macedonia, there is obligatory Bacillus Calmette--Guerin (BCG) vaccine for all newborn. Besides this, the results showed that nearly one-third of evaluated cases were with the negative status of BCG vaccination ([Table 6](#T6){ref-type="table"}).

###### 

BCG status of cases with LTBI

  BCG status   n (%)
  ------------ -------------
  Positive     51 (69.86)
  Negative     21 (28.77)
  Unknown      1 (1.37)
  Total        73 (100.00)

Regarding different treatment regime for LTBI, 50 cases received daily regime with H for 6 months and 23 cases received daily regime of H/R for 3 months ([Table 7](#T7){ref-type="table"}).

###### 

Different treatment regime for LTBI

  Treatment regimes                   n (%)
  ----------------------------------- -------------
  6 months Isoniazid                  50 (68.49)
  3 months Isoniazid and Rifampicin   23 (31.51)
  Total                               73 (100.00)

Treatment outcomes showed that 75.34% of treated cases with LTBI completed treatment, and only 13.69% did not finish the whole regime ([table 8](#T8){ref-type="table"}).

###### 

Treatment outcomes in 73 cases with LTBI

  Treatment outcomes                                  n (%)
  --------------------------------------------------- -------------
  Completed treatment                                 55 (75.34)
  Interrupted treatment                               10 (13.69)
  Interrupted treatment due to negative control TST   8 (10.96)
  Total                                               73 (100.00)

In an aim to evaluate if there were some factors that influenced the treatment outcome, the correlation test was performed between the gender, age groups, different risk groups for detecting LTBI, different therapeutic regimes and the treatment outcomes, and we did not find any statistically significant correlation ([Table 9](#T9){ref-type="table"}).

###### 

Correlation of gender, age groups, risk groups and treatment regimes of cases with LTBI and treatment outcomes

                                       N            Treatment outcome   Interrupted due to negative control TST   
  ------------------------------------ ------------ ------------------- ----------------------------------------- -----------
  Gender                                                                                                          
   Men                                 45 (61.64)   7 (70)              33 (60)                                   5 (62.5)
   Women                               28 (38.36)   3 (30)              22 (40)                                   3 (37.5)
  Fisher exact, two-tailed p = 0.9                                                                                
  Age groups                                                                                                      
   0 -- 4                              21 (28.77)   2 (20)              16 (29.09)                                3 (37.5)
   5 -- 14                             40 (54.79)   6 (60)              29 (52.73)                                5 (62.5)
   15 -- 24                            2 (2.74)     1 (10)              1 (1.82)                                  0
   25 -- 34                            4 (5.48)     0                   4 (7.27)                                  0
   45 -- 54                            5 (6.85)     1 (10)              4 (7.27)                                  0
   55 -- 64                            1 (1.37)     0                   1 (1.82)                                  0
  Fisher exact, two-tailed p = 0.875                                                                              
  Risk groups                                                                                                     
   Contact with TB                     61 (83.56)   8 (80)              45 (81.81)                                8 (100.0)
   PLHIV                               9 (12.33     2 (20)              7 (12.73)                                 0
   Others                              3 (4.11)     0                   3 (5.45)                                  0
  Fisher exact, two-tailed p = 0.54                                                                               
  Treatment regime                                                                                                
   6 months H                          50 (68.49)   7 (70)              38 (69.09)                                5 (62.5)
   3 months H/R                        23 (31.51)   3 (30)              17 (30.91)                                3 (37.5)
  Fisher exact, two-tailed p = 0.54                                                                               

Discussion {#sec1-4}
==========

The presented study shows our results of using two tests (TST and IGRA) for detecting the LTBI in the Republic of Macedonia and treatment outcomes: in 2016 there were 73 cases diagnosed with LTBI that received preventive therapy. In Macedonia, for many years ago, only TST was used for screening the LTBI mostly among children household contacts of pulmonary TB cases; we did not use this test for screening LTBI among the adults even they were contacts with TB cases. All these adult contacts according to our NTP were screened only for active TB. Because BCG vaccination is obligatory for all newborns in Macedonia, it was difficult to interpret TST positive results: whether they are due to the cross-reaction with BCG vaccination, or to the infection with Mycobacterium tuberculosis. In 2013, IGRA test with high specificity was introduced for screening LTBI in our NTP which meant to reduce false positivity due to BCG vaccination or nontuberculous mycobacteria (NTM) infection. In the beginning its indication was limited only to children contacts with TB cases and PLHIV, and after this first period we expanded the indication according to the recommendation from Guidelines on the management of latent tuberculosis infection \[[@ref5]\] to the patients initiating anti-tumor necrosis factor (TNF) treatment, patients receiving dialysis, patients preparing for organ or hematologic transplantation, and patients with silicosis, but its implementation was going very slowly. There is a modification in the Macedonian Guidelines for LTBI in 2016, from the 2008 Guidelines. In 2016 there were only 9 cases with PLHIV and 3 cases with other medical risk factors screened and treated of LTBI.

All cases with LTBI in this study were not screened with both tests: according to our practice for many years ago, TST was performed in all children -61 and only in1 adults (62-84.93%). IGRA was performed in half of the cases (37-50.68%): 12 adults and 25 children.

According to the data from the literature, there is no ideal test for detecting Mycobacterium tuberculosis infection even both tests are moderately sensitive and highly specific \[[@ref7]\]. The disadvantages of TST include the need for two visits (to place the TST and to read it 48-72 hours later), inter-reader variability in measuring millimetres of induration, diminished response caused by immunosuppression, boosting on repeat testing, and potential cross-reaction with nontuberculous mycobacteria and *M. bovis* BCG vaccine \[[@ref8]\]. The introduction of the IGRA was an advance in diagnostic technology. IGRA detect LTBI by measuring IFN-gamma release in response to antigens present in Mycobacterium tuberculosis, but not BCG vaccine and most nontuberculous mycobacteria.

The evidence base for these tests has expanded rapidly and now, the result of some systematic reviews indicate that in comparison to TST, IGRAs can detect LTBI with a higher specificity, negative (NPV) and positive (PPV) predictive values, as they are not confounded by previous BCG vaccination \[[@ref9]\] \[[@ref10]\] \[[@ref11]\].

Regarding the treatment regimes we use two regimes: 50 cases (68.44%) received 6months daily regime with H, and 23 cases (31.51%) received 3months daily regime with HR. We have to comment that according to our results there were 24 cases without laboratory confirmation of LTBI, but besides that, they were treated with preventive therapy for LTBI. This was because they were children at 5 or under the age of 5 with very close household contact with pulmonary TB. It is according recommendations by WHO and other association that people living with HIV and children under the age of 5 years who are close household or close contact with people with TB and who have negative TST or IGRA results (with normal chest radiograph) should be treated for LTBI and another TST or IGRA performed 8-10 weeks after contact has ended. If a repeat TST or IGRA result is positive, treatment should be continued. If it is negative, treatment can usually be discontinued \[[@ref5]\] \[[@ref12]\] \[[@ref13]\].

According to the Guidelines from WHO and the Centers for Disease Control and Prevention (CDC) there are four treatment regimes for LTBI: 9 or 6 months of daily self-administered H, 4 months of daily self-administered R, 3 months of daily self -administered H/R, and the newest 3 months of once-weekly directly observed isoniazid-rifapentine \[[@ref5]\]\[[@ref14]\]. WHO recommends either 6 or 9 months of daily 9H as the standard for treatment of LTBI \[[@ref5]\]. For people living with HIV infection, 9 months of therapy is recommended. The benefits of preventive therapy to individuals with LTBI have been demonstrated in some randomised clinical trials \[[@ref15]\] \[[@ref16]\].

The results from this study showed that most patients completed treatment regimes: 55 (75.34%) and only 10 (13.09%) interrupted the treatment. 8 (10.96%) of them interrupted treatment because of negative control TST after 8 weeks of the window period. We did not find that some factors such as gender, age groups, different risk groups or treatment regimes correlated with the treatment outcomes. In our study cases, we did not register some serious adverse effects from therapy. In the study of Denholm et al. even adverse effects were frequently identified among the cases with LTBI, there were also, high levels of treatment adherence and completion \[[@ref17]\]. The analysis from some studies identified the following determinants as detrimental to treatment completion: adverse drug reactions, longer duration of treatment, immigrant status, long distance from a health facility, the presence of stigma, alcohol and drug use, unemployment and time lag between diagnosis and treatment \[[@ref5]\]. One randomised trial showed a significant increase in completion rate in the 3-month weekly rifapentine plus isoniazid regimen compared to the 9-month isoniazid regimen \[[@ref18]\].

Analysis of this study presented the program for diagnosis and treatment of LTBI in Macedonia and compared the findings with the actual recommendations. When the IGRA's has been introduced in our program, big progress was made in the widening the indication for detecting LTBI. Detecting and treating cases who are at risk to develop active TB, will contribute to better control of TB in Macedonia. Using IGRA tests among household contacts with pulmonary TB will help for better selection of cases that need preventive therapy. Despite the progress, several challenges remain to be addressed: further strengthening in the optimum use of both tests, to assess the ability of these tests to predict tuberculosis disease, their reproducibility over serial tests, and discordance between tests. Regarding the treatment as soon as possible we should provide the use of 3 months of once-weekly directly observed isoniazid-rifapentine regime.
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